Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced a $40 million dollar upgrade of its single‑use technology manufacturing facility in Millersburg, Pennsylvania, USA. The expansion comes as part of a long-term, $650 million investment plan unveiled in 2021 to improve bioprocessing production capacity for critical materials used in developing new and existing biologics and vaccines.
The investment will create a new 47,000-square-foot warehouse at the site, with an additional 100 new hires as Thermo Fisher cites its belief that the site will employ more than 1000 workers once it is fully renovated by 2023.
Single-use technologies are essential in the development of a growing number of biological drugs and vaccines, and has created unprecedented demand for these products. The Millersburg site expansion will add significant capacity to continue providing the biopharma industry with the technology and materials needed to assist in developing new vaccines, cancer treatments, and breakthrough therapies for other conditions.
For more information, please visit: https://corporate.thermofisher.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.